Skip to main content

17-07-2018 | Adalimumab biosimilar | News


EMA backs new adalimumab biosimilar

medwireNews: The European Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of the adalimumab biosimilar GP2017 for the treatment of various rheumatic diseases.

The biosimilar will be marketed under three brand names; Hyrimoz and Halimatoz are indicated for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), axial spondyloarthritis, and psoriatic arthritis (PsA), as well as other conditions including psoriasis and uveitis. Hefiya is also recommended for patients with JIA, axial spondyloarthritis, and PsA, but the list of indications does not include RA.

As with the originator product, GP2017 will be available as a 40 mg solution for subcutaneous injection.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

Related topics

More on this topic

13-12-2017 | Biosimilars | Feature | Article

Biosimilars: The story so far

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

Image Credits